

New Clinical Trial Opportunity

• Relapsing Multiple Sclerosis

SiteRx is excited to announce the launch of a new clinical research study in partnership with Novartis Pharmaceuticals. Now available to all network providers

Clinical Trial Summary

- EXCHANGE is a large Phase III trial
- 6-month, single treatment arm, open-label interventional trial for patients with advancing forms of Relapsing MS with or without progressive features.
- Exploring conversion from oral, injectable, or infusion DMT to oral Sponimod. Sponimod, Mayzent was FDA approved for MS in 2019.
- Conversion to sponimod is overseen by study PI after entering trial.
- Time sensitive recruitment window ends as early as June 2021

Key Inclusion Criteria

- Adults ages 18-65 diagnosed with Relapsing MS with or without Secondary Progressive MS
- Currently on DMT for at least 3 months or patients not on DMT at time of screening.
- EDSS score > 2.0 – 6.5

Key Exclusion Criteria

- Current use of cannabinoid or cannabidiol products.
- Medically unstable
- Stable medications changing memory or other medication is a top reason for disqualification, but patients can stay on medication throughout the trial

Questions about EXCHANGE?

Contact your Clinical Trial Advocate Today:
Hello@SiteRx.com



**Immediate
Patient Need**

400

EXCHANGE is actively recruiting Phase III study, targeting patients with Relapsing Multiple Sclerosis



**Patient Site
Options**

SiteRx is launching EXCHANGE at multiple sites in core geographies, providing maximal convenience to interested patients